DiaSys Corporation (DYX) Presents Additional Patent Claims For Unique In Vitro Assay Technology To Detect And Monitor Kidney Failure Or Malfunction
10/19/2005 5:11:31 PM
DiaSys Corporation (AMEX: DYX) a global healthcare products company announced that it presented additional patent claims for it's unique in vitro assay technology to detect and monitor kidney disease. Kidney malfunction may go undetected by current methods of testing until 80% or more of the kidney is damaged. The technology is quick, easy to use and inexpensive, providing front-line testing for early detection before the kidney degenerates or fails. The claims include monitoring, screening and adjunctive testing for renal (kidney) insufficiency and renal (kidney) failure due to diabetes, hypertension and monoclonal gammopathies. DiaSys Corporation has also presented an additional device claim to include a home testing configuration of its technology.
comments powered by